

Safety Data Sheet (SDS) According to the REACH Regulation (EC) No. 1907/2006

Issuing Date: 2015-01-12

Revision Date: 2018-03-26

Version: 3

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product No 12017
Product name Everolimus
Reach registration number This substance/mixture contains only ingredients which have been registered, or are exempt from registration, according to Regulation (EC) No. 1907/2006.

Contains

Formula $C_{53}H_{83}NO_{14}$
Molecular Weight 958.22 g/mol

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses For research use only

1.3. Details of the supplier of the safety data sheet

Importer (Applicable in EU only)	Manufacturer
Cell Signaling Technology Europe B.V.	Cell Signaling Technology, Inc.
Schuttersveld 2	3 Trask Lane
2316 ZA Leiden	Danvers, MA 01923
The Netherlands	United States
TEL: +31 (0)71 7200 200	TEL: +1 978 867 2300
FAX: +31 (0)71 891 0098	FAX: +1 978 867 2400

Website www.cellsignal.com
E-mail Address info@cellsignal.eu

1.4. Emergency telephone number

CHEMTREC 24 hours a day, 7 days a week, 365 days a year
+1 703 527 3887 (INTERNATIONAL) +1 800 424 9300 (NORTH AMERICA)

Europe 112

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No. 1272/2008

Reproductive toxicity	Category 1B - (H360Df)
Effects on or via lactation	Effects on or via lactation - (H362)
Specific target organ toxicity - repeated exposure (STOT RE)	Category 1 - (H372)
Chronic aquatic toxicity	Category 3 - (H412)

2.2. Label elements**Signal word**

Danger

Hazard statement(s)

H360Df - May damage the unborn child. Suspected of damaging fertility

H362 - May cause harm to breast-fed children

H372 - Causes damage to organs through prolonged or repeated exposure

H412 - Harmful to aquatic life with long lasting effects

Precautionary statement(s)

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P263 - Avoid contact during pregnancy/while nursing

P264 - Wash face, hands and any exposed skin thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P273 - Avoid release to the environment

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container to an approved waste disposal plant

2.3. Other hazards

For the full text of the H-phrases & EUH-phrases mentioned in this Section, see Section 16

SECTION 3: Composition/information on ingredients

3.1 Substances**Synonyms**

Everolimus;

42-O-(2-hydroxyethyl)-rapamycin (9CI);

Afinitor®;

Zortress®;

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{{

(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}}

-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxo-4-aza-tricyclo[30.3.1.0^{4,9}]-hex

atriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone

FormulaC₅₃H₈₃NO₁₄**Chemical nature**

Monoconstituent substance.

Chemical Name	CAS No	Weight %	EC No	Classification (1272/2008)	REACH Registration Number
Everolimus	159351-69-6	100	-	Repr. 1B (H360Df) Lact. (H362) STOT RE 1 (H372) Aquatic Chronic 3 (H412)	no data available

For the full text of the R-phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures

4.1. Description of first aid measures

General advice	Use first aid treatment according to the nature of the injury. When symptoms persist or in all cases of doubt seek medical advice.
Inhalation	Move to fresh air.
Skin contact	Wash off immediately with soap and plenty of water removing all contaminated clothes and shoes.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Ingestion	Clean mouth with water and afterwards drink plenty of water.

4.2. Most important symptoms and effects, both acute and delayed

Fatigue. stomatitis. infection. rash. Diarrhea. Edema. Abdominal pain. Nausea. Fever. Asthenia. Shortness of breath or cough. Headache. Loss of appetite.

4.3. Indication of any immediate medical attention and special treatment needed

Notes to physician Treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable Extinguishing Media	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Unsuitable Extinguishing Media	No information available.

5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

5.3. Advice for firefighters

Wear self-contained breathing apparatus and protective suit. Use personal protective equipment.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	Evacuate personnel to safe areas. Ensure adequate ventilation.
For emergency responders	Use personal protection recommended in Section 8.

6.2. Environmental precautions

Should not be released into the environment. Prevent further leakage or spillage if safe to do so. Local authorities should be advised if significant spillages cannot be contained.

6.3. Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Take up mechanically, placing in appropriate containers for disposal.

6.4. Reference to other sections

See Sections 8 & 13 for additional information.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

7.3. Specific end use(s)

Use as a laboratory reagent.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

8.2. Exposure controls

Appropriate engineering controls

Showers, eyewash stations, and ventilation systems.

Individual protection measures, such as personal protective equipment

Eye/face protection	Safety glasses with side-shields
Skin protection	
Hand protection	Impervious gloves.
Other	Wear suitable protective clothing.
Respiratory protection	In case of inadequate ventilation wear respiratory protection.

Environmental Exposure Controls

No information available.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state	Solid
Appearance	Powder
Color	White to off-white
Odor	No information available
Odor Threshold	No information available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
pH	5.1 - 5.2	@ 10 g/L in water
Melting point/freezing point		No information available
Initial boiling point and boiling range		No information available
Flash point		No information available.
Evaporation rate		No information available
Flammability (solid, gas)		No information available
Upper flammability limit		No information available
Lower flammability limit		No information available
Vapor pressure		No information available
Vapor density		No information available
Relative density		No information available
Solubility		No information available
Partition coefficient: n-octanol/water		No information available

12017 Everolimus

Autoignition temperature	No information available
Decomposition temperature	No information available.
Viscosity	No information available
Explosive properties	No information available
Oxidizing properties	No information available

9.2. Other information

Softening point	No information available
Molecular Weight	958.22 g/mol
Solubility in other solvents	No information available
VOC content	No information available
Density	No information available.

SECTION 10: Stability and reactivity

10.1. Reactivity

No information available.

10.2. Chemical stability

Stable under normal conditions.

10.3. Possibility of hazardous reactions

Hazardous polymerization	Hazardous polymerization does not occur.
Hazardous reactions	None under normal processing.

10.4. Conditions to avoid

None known based on information supplied.

10.5. Incompatible materials

No information available.

10.6. Hazardous decomposition products

None under normal use conditions.

SECTION 11: Toxicological information

11.1. Information on toxicological effects

This material should only be handled by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals. It should be borne in mind that the toxicological and physiological properties of this compound is not well defined.

Chemical Name	LD50 Oral	LD50 Dermal	LC50 Inhalation
Everolimus	> 2000 mg/kg (Rat)	-	-

Information on likely routes of exposure

Inhalation	May cause irritation of respiratory tract.
Eye contact	Contact with eyes may cause irritation.
Skin contact	May cause irritation.
Ingestion	May be harmful if swallowed. Target Organ Effects.
Symptoms	Fatigue. stomatitis. infection. rash. Diarrhea. Edema. Abdominal pain. Nausea. Fever. Asthenia. Shortness of breath or cough. Headache. Loss of appetite.
Skin corrosion/irritation	not applicable.

12017 Everolimus

Serious eye damage/eye irritation	No information available.
Sensitization	Did not cause sensitization on laboratory animals.
Mutagenic effects	Not mutagenic in AMES Test. Negative in an in vivo rat micronucleus test. Negative in the chromosomal aberration assay.
Carcinogenic effects	Did not show carcinogenic effects in animal experiments.
Reproductive toxicity	This material is classified as a Pregnancy Category D: Positive evidence of risk. In a male fertility study in rats, testicular morphology was affected at 0.5 mg/kg and above, and sperm motility, sperm head count, and plasma testosterone levels were diminished at 5 mg/kg. Female fertility was not affected, but everolimus crossed the placenta and was toxic to the foetus. Everolimus and/or its metabolites passed into the milk of lactating rats at a concentration 3.5 times higher than in maternal serum.
Teratogenicity	In rats, everolimus caused embryo/foetotoxicity at systemic exposure. This was manifested as mortality and reduced foetal weight. The incidence of skeletal variations and malformations (e.g. sternal cleft) was increased at 0.3 and 0.9 mg/kg. In rabbits, embryo toxicity was evident in an increase in late resorptions.
STOT - single exposure	No information available.
STOT - repeated exposure	The major target organs were male and female reproductive systems (testicular tubular degeneration, reduced sperm content in epididymides and uterine atrophy) in several species; lungs (increased alveolar macrophages) in rats and mice; pancreas (degranulation and vacuolation of exocrine cells in monkeys and minipigs, respectively, and degeneration of islet cells in monkeys), and eyes (lenticular anterior suture line opacities) in rats only.
Target Organ Effects	Immune system, Reproductive system, Lungs, Pancreas, Eyes.
Aspiration Hazard	No information available.
Other information	No information available.

SECTION 12: Ecological information

12.1. Toxicity

Harmful to aquatic life with long lasting effects

Chemical Name	Toxicity to algae	Toxicity to fish	Toxicity to daphnia and other aquatic invertebrates
Everolimus	-	LC50 >18.4 mg/L (Cyprinus carpio) 96 h	-

12.2. Persistence and degradability

Not readily biodegradable. 2% 28 day period.

12.3. Bioaccumulative potential

Bioaccumulation	Not likely to bioaccumulate.
Bioconcentration factor (BCF)	No information available.

Chemical Name	Octanol-Water Partition Coefficient
Everolimus	4

12.4. Mobility in soil

Is not likely mobile in the environment due its low water solubility.

12.5. Results of PBT and vPvB assessment

This substance is not considered to be persistent, bioaccumulating nor toxic (PBT).

12.6. Other adverse effects

No information available

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues / unused products	Dispose of in accordance with local regulations.
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal.
Other information	Waste codes should be assigned by the user based on the application for which the product was used.

SECTION 14: Transport information

IMDG/IMO

14.1 UN number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing group	Not regulated
14.5 Environmental hazards	None
14.6 Special precautions for user	None
14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not regulated

ADR/RID

14.1 UN number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing group	Not regulated
14.5 Environmental hazards	None
14.6 Special precautions for user	None

IATA

14.1 UN number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing group	Not regulated
14.5 Environmental hazards	None
14.6 Special precautions for user	None

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Candidate List of Substances of Very High Concern for Authorization Information

This product does not contain Substances of Very High Concern (SVHC).

SEVESO Directive Information

This product does not contain substances identified in the SEVESO Directive.

International inventories

TSCA 8(b)	-
DSL/NDL	-
EINECS/ELINCS	-
ENCS	-
IECSC	-
KECL	-
PICCS	-
AICS	-

International inventories legend

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

For this substance a chemical safety assessment has not been carried out

SECTION 16: Other information

Full text of H-Statements referred to under Sections 2 and 3

H360Df - May damage the unborn child. Suspected of damaging fertility

H362 - May cause harm to breast-fed children

H372 - Causes damage to organs through prolonged or repeated exposure if inhaled

H412 - Harmful to aquatic life with long lasting effects

Classification procedure: Expert judgment and weight of evidence determination.

Issuing Date: 2015-01-12

Revision Date: 2018-03-26

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.